Jill O'Donnell-Tormey - 18 May 2022 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role: Director
Signature: /s/ McDavid Stilwell, as Attorney-in-Fact for Jill O'Donnell-Tormey
Issuer symbol: CHRS
Transactions as of: 18 May 2022
Net transactions value: $0
Form type: 4
Filing time: 20 May 2022, 16:58:22 UTC
Next filing: 09 Jun 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CHRS	Stock Option (Right to Buy)	Award	$0	+54,000		$0.000000	54,000	18 May 2022	Common Stock	54,000	$7.45	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The underlying shares subject to the option vest and become exercisable as to 1/36th of the total number of shares subject to the option in successive, equal monthly installments measured from May 18, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.